1 and other preventative therapies that target encapsulated pathogens.

2 en proposed as antigens for vaccines against encapsulated pathogens.

3 ther consideration as vaccine candidates for encapsulated pathogens.

4 mplexes during the course of infections with encapsulated pathogens.

5 o induce protective immune responses against encapsulated pathogens.

6 late that this model may also apply to other encapsulated pathogens.

7 ation for its role in protection against non-encapsulated pathogens.

8 d to develop more effective vaccines against encapsulated pathogens.

9 dy in response to infection with blood-borne encapsulated pathogens.

10 ism of Ab function, which may apply to other encapsulated pathogens.

11 gs reveal a role for NOD1 in protection from encapsulated pathogens.

12     Based on the success achieved with other encapsulated pathogens, a glycoconjugate vaccine strateg

13 ble strategy against invasive polysaccharide-encapsulated pathogens, and lipopolysaccharide (LPS) is

14 psules are critical for host defense against encapsulated pathogens, but very little is known about t

15 roven effective against infections caused by encapsulated pathogens, there is still no Klebsiella pne

16 y B cells are required for immunity to other encapsulated pathogens, we hypothesized that these cells